ESR1 and triple-negative breast carcinoma: Other subtypes, including estrogen receptor-positive HER2-negative (ER+HER2−) and triple-negative breast cancer (TNBC), showed 20–22% Group 1 and 27–32% Group 2 patient distributions (Table 3).